Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIELD: Safety of tirzepatide after curative HCC treatment in patients with steatotic liver disease and obesity
jRCT1031250836Recruiting
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of tirzepatide in obesity, steatosis, hepatocellular carcinoma (HCC) and 3 more. Primary endpoint: Incidence of serious acute pancreatitis regardless of causality. Started Mar 2026; status: recruiting.
02
Drugs
03
Conditions
obesitysteatosishepatocellular carcinoma (HCC)hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on jRCT1031250836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250836.